Furosemide effect on mineral status of parenterally nourished premature neonates with chronic lung disease.
In this study, the effect of prolonged furosemide administration on calcium and phosphorus homeostasis was examined in 16 parenterally nourished very low birth weight infants with chronic lung disease. Patients received one of three different dosages of phosphorus: low, 0.91 +/- 0.06 mmol/kg per day; moderate, 1.24 +/- 0.02 mmol/kg per day; and high, 1.64 +/- 0.06 mmol/kg per day. All furosemide-treated patients had high levels of urinary calcium (12.1 +/- 2.2 mg/kg per day), phosphate (19.1 +/- 2.7 mg/kg per day), and cyclic 3'5'-adenosine monophosphate (76.8 +/- 6.7 nmol/kg per day) excretion, independent of their phosphorus intake. Parathyroid hormone concentrations were high in furosemide-treated patients (0.95 +/- 0.15 ng/mL) compared with patients not treated with furosemide and receiving either moderate (0.49 +/- 0.05 ng/mL) or low (0.42 +/- 0.07 ng/mL) phosphorus intakes. Furosemide administration may lead to secondary hyperparathyroidism.
Vileisis
R A
RA
Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710.
D000249:Adenosine Monophosphate / Q000652:urine; D002118:Calcium / Q000652:urine*; D002908:Chronic Disease; D005665:Furosemide / Q000009:adverse effects*; D006706:Homeostasis; D006801:Humans; D006961:Hyperparathyroidism / Q000139:chemically induced*; D007231:Infant, Newborn; D007234:Infant, Premature; D008171:Lung Diseases / Q000188:drug therapy; D010289:Parenteral Nutrition, Total; D010758:Phosphorus / Q000008:administration & dosage / Q000652:urine*
D010758:Phosphorus; D000249:Adenosine Monophosphate; D005665:Furosemide; D002118:Calcium